1 **Title: Population pharmacokinetic modeling of pyrotinib in patients with**
2 **HER2-positive advanced or metastatic breast cancer**

3 Hai-ni Wen¹, Yi-xi Liu^{1,2}, Da Xu³, Kai-jing Zhao³, Zheng Jiao¹

4 ¹Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
5 Shanghai, P.R.China

6 ²Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, P.R.China

7 ³Department of Clinical Pharmacology, Jiangsu Hengrui Medicine Co. Ltd, Shanghai,
8 P.R.China

9

10 **Correspondence:**

11 Zheng Jiao, Professor

12 ¹Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
13 Huaihai West Road, Shanghai, China, 200030

14 Tel.: +86 (21) 2220 0000

15 E-mail: jiaozhen@online.sh.cn;

16 ORCID: 0000-0001-7999-7162

17

18 # Hai-ni Wen and Yi-xi Liu has made equal contributions to this work.

19

20 **Abstract**

21 **Objective:** Pyrotinib, a novel oral irreversible dual pan-ErbB tyrosine kinase inhibitor
 22 (TKI), has been approved in China for the treatment of HER2-positive advanced or
 23 metastatic breast cancer. This study aimed to conduct a population pharmacokinetics
 24 (PK) analysis of pyrotinib and to evaluate the impact of certain HER2-positive breast
 25 cancer patient characteristics on pyrotinib's PK.

26 **Method:** A total of 1152 samples, provided by 59 adult female patients from two
 27 phase I clinical trials, were analyzed by nonlinear mixed-effects modeling. Monte
 28 Carlo simulation was conducted to assess the impact of covariates following exposure
 29 to pyrotinib.

30 **Results:** The PK of pyrotinib was adequately described by a one-compartment model
 31 with first-order absorption and elimination. Patient's age and total protein levels can
 32 affect pyrotinib's apparent volume of distribution, and concomitant use of
 33 montmorillonite powder had significant effects on the bioavailability of pyrotinib. No
 34 PK interactions were observed between capecitabine and pyrotinib.

35 **Conclusion:** In this study, a population PK model of pyrotinib was developed to
 36 determine the influence of patient characteristics on the PK of pyrotinib. While
 37 patient age and total protein levels can significantly affect the apparent distribution
 38 volume of pyrotinib, the magnitude of the impact was limited, thus no dosage
 39 adjustment was recommended. Furthermore, concomitant use of montmorillonite
 40 powder for diarrhea can decrease the bioavailability of pyrotinib by 50.3%.

41 **Keywords:** Pyrotinib, tyrosine kinase inhibitor, population pharmacokinetics, Monte
42 Carlo simulation, HER2-positive, breast cancer.

43 **Abbreviations**

44 ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC,
45 concentration-time curve; BMI, body mass index; BSV, between-subject variability;
46 BW, body weight; CL/F, apparent clearance; CYP, cytochrome P450; CWRES,
47 conditional weighted residual error; eGFR, estimated glomerular filtration rate; GOF,
48 goodness-of-fit; HER, human epidermal growth factor receptor; *ka*, absorption rate
49 constant; LLOQ, lower limit of quantitation; pcVPC, prediction corrected visual
50 prediction check; popPK, population PK; PK, pharmacokinetics; RUV, residual
51 unexplained variability; SCr, serum creatinine; TB, total bilirubin; TKI, tyrosine
52 kinase inhibitors; TP, total protein; Vd/F, apparent volume of distribution.

53 1. Introduction

54 Pyrotinib is an oral, irreversible dual pan-ErbB tyrosine kinase inhibitor (TKI) that
 55 potently inhibits human epidermal growth factor receptor (HER) 1 and 2¹. In August
 56 2018, the National Medical Products Administration of China authorized conditional
 57 approval of pyrotinib for the treatment of HER2-positive advanced or metastatic
 58 breast cancer in patients previously treated with anthracycline or taxane
 59 chemotherapy. A dosage of 400 mg of pyrotinib once daily after a meal was
 60 recommended². Furthermore, trials investigating the efficacy and safety of pyrotinib
 61 for other HER2-positive solid tumors, such as gastric cancer and non-small cell lung
 62 cancer, are on-going both in China and USA^{3,4}. Moreover, according to the result of a
 63 multicentered, randomized phase II clinical trial, pyrotinib and capecitabine treatment
 64 showed greater clinical benefits than lapatinib and capecitabine treatment in patients
 65 with metastatic breast cancer. The higher overall response rate (78.5% versus 57.1%)
 66 and favored progression-free survival (18.1 versus 7.0 months) indicate that pyrotinib
 67 is a promising drug among numerous HER-family TKIs⁵.

68 Following oral administration of pyrotinib (80-400 mg single dose), the time
 69 required to reach maximum plasma concentration (T_{max}) is 3-5 h^{6,7}. Maximum
 70 concentration (C_{max}) and area under the concentration-time curve (AUC) at steady
 71 state increased in a dose-dependent manner, indicating the linear pharmacokinetic
 72 (PK) profile of pyrotinib⁶. Steady-state plasma concentrations are reached within 8
 73 days of repeated administration. No major accumulation after repeated daily
 74 administration was observed in phase I clinical trials⁶. The apparent volume of

75 distribution (Vd/F) at steady-state was 3820 L/kg ⁷. During the elimination phase,
76 pyrotinib is mainly metabolized by the hepatic cytochrome P450 (CYP) 3A4 (>75%),
77 and mainly excreted in the feces (>90.9%) ^{8,9}.

78 The phase I clinical trials have shown high between-subject variability following
79 pyrotinib administration. The coefficients of variation of AUC_{0-24h} and C_{max} at
80 steady-state varied between 25-110% and 32.8-91%, respectively ^{6,7}. Moreover, *in*
81 *vivo* and *in vitro* studies have suggested high plasma protein binding rate (86.9-99.7%)
82 of pyrotinib, with 58.3% covalently bound to human plasma protein ^{1,8}. Therefore,
83 understanding potential factors that can affect the PK of pyrotinib in patient
84 populations is essential for individualized regimen dosing and optimized clinical
85 outcomes.

86 Population PK (popPK) approach enables a pooled PK analysis over data from
87 trials of heterogenous designs, as well as identification of sources of PK variability
88 within a defined population. The aim of this study was to describe the popPK of
89 pyrotinib in patients with HER2-positive advanced or metastatic breast cancer by pool
90 analyzing two phase I clinical trial studies. Furthermore, the impact of covariates on
91 pyrotinib PK, including patient demographics, biochemical laboratory tests, and
92 co-administration of other medications was assessed.

93 2 Methods

94 2.1 Study Design and Patients

95 The popPK analysis was conducted using data from two phase I, single-arm,
 96 open-label, pyrotinib dose-escalation clinical trial studies. In the BLTN-Ib
 97 (NCT01937689) study, patients with HER2-positive advanced breast cancer were
 98 treated with pyrotinib monotherapy, with dosage ranging between 80 and 480 mg
 99 once daily, in 28-day cycles⁷. In the BLTN-Ic (NCT02361112) study, patients with
 100 HER2-positive metastatic breast cancer were treated with pyrotinib in combination
 101 with capecitabine. The pyrotinib dosage ranged between 160 and 400 mg, which was
 102 administered orally once daily, and capecitabine 1,000 mg/m² was administered twice
 103 daily was from day 1 to 14 in 21-day cycles⁶. Intensive sampling was conducted in
 104 the first cycle of both regimens. A detailed description of the study design and PK
 105 sampling time points is summarized in [Table 1](#).

106 Both studies were conducted in accordance with the principles of the Declaration
 107 of Helsinki (October 2013) and the International Conference on Harmonization
 108 Guidelines for Good Clinical Practice¹⁰. Study protocols were approved by the ethics
 109 committee at each trial center. Informed consent was obtained from each participant
 110 included in each study^{6,7}.

111 **2.2 Bioanalytical Methods**

112 The plasma samples were stored at -70°C until analysis. Pyrotinib plasma
113 concentrations were measured using a validated liquid chromatography mass
114 spectrometry (LC/MS/MS) method. The lower limit of quantitation (LLOQ) was
115 0.429 ng/mL. The calibration range was 0.429 (LLOQ) to 215 ng/mL ^{6,7}.

116 **2.3 Data handling**

117 Patients were included for the PK analysis if they had ≥ 1 adequate dose and ≥ 1
118 corresponding pyrotinib plasma concentration result. Concentrations below the LLOQ
119 were excluded from the analysis. Through exploratory analysis, data with more than
120 six conditional weighted residual errors (CWRES) were considered potential outliers
121 and excluded from modelling analysis. Missing values were handled as follows: 1)
122 missing drug concentrations were documented and excluded from the analysis; 2) PK
123 data without a sampling time were excluded from the analysis; 3) covariates with data
124 missing for more than 10% of the patients were not included in the analysis.

125 **2.4 Population Pharmacokinetic Analysis**

126 A nonlinear mixed-effect modeling (NONMEM) approach was adopted to establish
127 population PK models, as implemented in the NONMEM software (version 7.4.0,
128 ICON Development Solutions, Ellicott City, MD, USA) with first-order conditional
129 estimation with the η - ϵ interaction (FOCE-I) method. Perl-speaks-NONMEM (PsN,
130 version 4.7.0, Department of Pharmaceutical Biosciences, Uppsala University,

Sweden) was used to perform visual predictive checks, covariate screening, and bootstrap analyses. SAS (version 9.4, SAS institute Inc, Cary, USA), R (version 3.4.1, R Foundation for Statistical Computing, Vienna, Austria) and R package “Xpose” (version 4.5.3, Department of Pharmaceutical Biosciences, Uppsala University, Sweden) were used for graphics analysis and data manipulation.

2.4.1 Base Model

Based on graphical exploratory analysis, one- and two-compartment models were selected as candidate structural models. Between-subject variability (BSV) was added as a structural pharmacokinetic parameter. BSV was applied based on an exponential model, as follows:

$$P_i = P_{pop} \cdot e^{(\eta_i)} \quad \text{Eq.1}$$

where P_i stands for the individual parameter estimate for individual i ; P_{pop} stands for the typical population parameter estimate; η_i depicts between individual random effects for individual i , which is assumed to adhere to a normal distribution with a mean of zero and variance of ω^2 .

Residual unexplained variability (RUV) was modelled as a proportional (Eq. 2), additive (Eq. 3) or a combination of a proportional error model and an additive error (Eq. 4) model:

$$Y_{ij} = IPRED_{ij} + \varepsilon_{a,ij} \quad \text{Eq. 2}$$

$$Y_{ij} = IPRED_{ij} \cdot (1 + \varepsilon_{p,ij}) \quad \text{Eq. 3}$$

$$Y_{ij} = IPRED_{ij} \cdot (1 + \varepsilon_{p,ij}) + \varepsilon_{a,ij} \quad \text{Eq. 4}$$

152 where Y_{ij} is the observed concentration for the individual i at time t_j ; $IPRED_{ij}$ is
 153 the individual predicted concentration; $\varepsilon_{p,ij}$ stands for the proportional error
 154 component, and $\varepsilon_{a,ij}$ stands for the additive error component. Residual error was
 155 assumed to adhere to a normal distribution with a mean of zero and variance of σ^2 .

156 Based upon Akaike's Information Criterion (AIC) ¹¹, as well as the precision of
 157 parameter estimates and visual inspection of goodness-of-fit (GOF) plots, the base
 158 model was constructed.

159 **2.4.2 Covariate Model**

160 Potential PK covariates were selected based on physiological and clinical relevance
 161 and included: age, total body weight (BW), body mass index (BMI), albumin,
 162 globulin, total protein (TP), aspartate aminotransferase (AST), alanine
 163 aminotransferase (ALT), total bilirubin (TB), serum creatinine (SCr), estimated
 164 glomerular filtration rate (eGFR), and occurrence of diarrhea. Co-administered
 165 medications were included in covariate analysis if more than 10% of patients received
 166 the medication.

167 All candidate covariates were first graphically explored to identify potential
 168 correlations and then carried through to subsequent analyses based on mechanistic
 169 plausibility and clinical relevance. Highly correlated covariates were identified
 170 through the graphical analysis and only one of the correlated covariates was used for
 171 further analysis.

172 Subsequently, potential covariates were examined using stepwise covariate

173 modeling method, including the forward inclusion and backward elimination process.
 174 During the forward inclusion process, the potential covariates were added to the base
 175 model one at a time, and the addition of one parameter required a significant decrease
 176 in objective function value (>3.84 , $p < 0.05$). A complete model was obtained when
 177 all significant covariates were included. During the backward elimination process,
 178 covariates from the complete model were removed one at a time, and the criterion for
 179 retention of a covariate was a significant change in objective function value (>10.83 ,
 180 $p < 0.001$) following the elimination.

181 Continuous covariates were assessed by both a linear function and a power
 182 function (Eq. 5 and 6), while categorical covariates were tested with Eq. 7:

$$183 \quad \theta_i = \theta_1 \cdot \theta_2 (\text{cov}_i / \text{cov}_{\text{median}}) \quad (\text{Eq. 5})$$

$$184 \quad \theta_i = \theta_1 \cdot (\text{cov}_i / \text{cov}_{\text{median}})^{\theta_2} \quad (\text{Eq. 6})$$

$$185 \quad \theta_i = \theta_1 \cdot \theta_2^{\text{cov}_i} \quad (\text{Eq. 7})$$

186 where θ_i and cov_i describe the parameter and covariate value for the individual i ,
 187 respectively. $\text{cov}_{\text{median}}$ is the median value for each covariate. θ_1 represents the
 188 typical value of a pharmacokinetic parameter at the median covariate value, and θ_2
 189 is an estimated value. In Eq. 7, cov_i equals to 0 or 1 for categorial variables.

190 **2.4.3 Model evaluation**

191 Model evaluation was performed by using GOF plots for model fitness. Scatterplots
 192 were used to evaluate the observed values *versus* population predicted values,
 193 observed values *versus* individual predicted values, CWRES *versus* population

194 predicted values, and CWRES *versus* time. In addition, nonparametric bootstrap
195 resampling (n = 2000) technique was employed for model evaluation. Each parameter
196 was calculated repeatedly by applying the final model to 2000 bootstrapped datasets.
197 The 2.5th and 97.5th percentiles and the median of the popPK parameter estimates
198 from the resampled datasets were compared with the estimates of the final model.

199 In order to adjust for differences of independent variables, a prediction corrected
200 visual predictive check (pcVPC) method was employed for simulation-based model
201 assessment¹². The pcVPC approach was conducted by simulating 1000 datasets using
202 the parameters of the final model, and by comparing the 5th and 95th percentiles and
203 the median in the observed data with the corresponding percentiles and median in the
204 simulated data. The concordance of variability and central tendency between the
205 observed and simulated data was evaluated.

206 **2.4.4 Model-based simulation**

207 Monte Carlo simulations were employed to evaluate the effect of covariates on the PK
208 of pyrotinib following 400 mg oral administration once daily. PK profile of a typical
209 reference patient (age 47 years, total protein 72.8 g/L) was compared to that of
210 patients with various covariate levels, which were set as 10th and 90th percentile of
211 population distribution. The predicted pyrotinib exposures were based on 1000
212 simulations for each group of patients, applying final model parameters for both fixed
213 and random effects.

214 3. Result

215 3.1 Patient characteristics and pharmacokinetic datasets

216 Out of 1436 PK data points from the original dataset, the final dataset contained a
 217 total of 1152 (80.22%) plasma samples, provided by 59 (19.5 samples per person)
 218 adult patients from BLTN-Ib (36 patients, 670 samples) and BLTN-Ic study (23
 219 patients, 482 samples). According to prespecified exclusion criteria, 284
 220 concentrations were excluded from the analysis: there were 79 observations (42 from
 221 BLTN-Ib study and 37 from BLTN-Ic study) below LLOQ; records of sampling time
 222 were missing for 205 data points (170 samples from BLTN-Ib and 35 from BLTN-Ic).
 223 No data were recognized as outliers.

224 Patient demographics, laboratory measurements, and co-administered
 225 medications are summarized in [Table 2](#). The female adult patients diagnosed with
 226 HER2-positive advanced or metastatic breast cancer enrolled in the PK analysis had a
 227 median age of 47 years old and a median body weight of 61 kg. More than 90% of the
 228 participants had total protein levels within the reference range (60–83 g/L) and most
 229 patients had normal renal and hepatic functions. Interestingly, the occurrence of
 230 diarrhea was much higher in patients from the BLTN-Ic group (19.60%) than that of
 231 the BLTN-Ib group (5.68%). The patients from the BLTN-Ic group were administered
 232 montmorillonite powder for diarrhea treatment. Overall, 68 out of 115 (59.13%) PK
 233 data points were sampled from patients receiving montmorillonite powder for

234 diarrhea treatment. In addition, patients with concomitant use of capecitabine and
235 pyrotinib were all from the BLTN-Ic group.

236 **3.2 Population-Pharmacokinetic Model**

237 **3.2.1 Base Model**

238 PK data from the two studies were best described using a one-compartment model
239 with first-order absorption and elimination. The adoption of a one-compartment
240 model showed increased precision of parameters and decreased Akaike's information
241 criterion by 306.7, compared to the two-compartment model. The model was
242 parameterized by apparent clearance (CL/F), Vd/F, and absorption rate constant (k_a).
243 The BSV was incorporated into all parameters. A combination of proportional and
244 additive error model was adopted for RUV in BLTN-Ib and BLTN-Ic studies
245 respectively, considering that PK sampling time as well as concomitant medications
246 were different in the two studies.

247 **3.2.2 Covariate Model**

248 Graphical exploratory analysis revealed that the BMI was correlated with BW;
249 albumin and globulin were correlated with TP; ALT was correlated with AST; SCr
250 was correlated with eGFR. Therefore, BW, AST, TP, and eGFR were selected as
251 covariate candidates due to their clinical relevance. Based on visual examination, the
252 effects of age, TB, and AST were evaluated as covariates of CL/F, while the effects of
253 age, BW, and TP were evaluated as covariates of Vd/F. The co-administration of

pyrotinib with montmorillonite powder or capecitabine were evaluated as covariates of all parameters. Occurrence of diarrhea was evaluated as a covariate of k_a and bioavailability.

During the forward inclusion step, the effects of TP, age, AST, co-administration of capecitabine, and co-administration of montmorillonite powder were included, while AST and co-administration of capecitabine were eliminated in the subsequent backward elimination step. The major steps in the base and covariate model building are provided in [Supplementary Material \(Table S1\)](#).

The final model is listed below:

$$\begin{cases} CL/F(L/h) = 147 \\ Vd/F(L) = 2270 \cdot (AGE/47)^{0.654} \cdot (TP/72.9)^{-1.94} \\ k_a(1/h) = 0.357 \\ F = 0.497(\text{if montmorillonite powder is coadministered}) \end{cases}$$

The parameters of the final model are shown in [Table 3](#). All shrinkages of BSV and RUV were less than 30%, suggesting a reliable estimate of each parameter. Of noted, the inclusion of TP and age as covariates of Vd/F has led to a decrease of BSV from 45.72% to 40.12%, indicating that 5.6% of BSV in Vd/F was explained by TP and age. Co-administration of montmorillonite powder for diarrhea treatment can decrease the bioavailability of pyrotinib by 50.3%. Co-administration of capecitabine showed no effects on the PK of pyrotinib.

271 3.2.3 Model Evaluation

272 The GOF diagnostic plots of the final model ([Fig. 1](#)) showed adequate agreement
273 between predicted and observed pyrotinib plasma concentration values, with no
274 indication of model bias over a wide range of concentrations. Over time and across
275 predicted pyrotinib plasma concentration values no bias was observed in CWRES,
276 suggesting that the final model adequately described the PK of pyrotinib. The final
277 model was resampled 2000 times by non-parametric bootstrapping, with 1984
278 computations successfully presenting the minimization step. The bootstrapped median
279 and 2.5th and 97.5th percentile values of each parameter were consistent with the
280 final model parameter estimates ([Table 3](#)).

281 As presented in [Figure 2](#), the pcVPC assessment demonstrated that the final
282 model adequately characterized the trend of the concentration-time profile. Overall,
283 the pcVPC plots showed that the median, 5th and 95th percentile of the simulated
284 pyrotinib concentrations largely overlapped with the observed values, indicating a
285 reasonable predictive performance of the final model.

286 3.2.4 Model-based simulation

287 The simulated PK profiles of pyrotinib following administration of 400 mg once daily
288 in patients of varying TP levels and ages are shown in [Figure 3](#). Higher steady-state
289 pyrotinib concentrations were observed in younger patients and patients with higher
290 TP levels. Furthermore, the simulated concentration-time profiles suggested that age
291 and TP levels had limited effects on plasma concentration of pyrotinib.

292 4.Discussion

293 In this study, for the first time, a pyrotinib popPK model was developed, using a total
 294 of 1152 pyrotinib plasma samples from 59 adult female patients with HER2-positive
 295 advanced or metastatic breast cancer. A one-compartment model with first-order
 296 absorption and first-order elimination obtained the best description for the pyrotinib
 297 profile. The final model-derived typical values of pyrotinib PK were 147 L/h for CL/F,
 298 2270 L for Vd/F, and 0.352 for absorption constant k_a .

299 While age and TP levels were identified as significant covariates of pyrotinib
 300 Vd/F during popPK modelling process, the effects of both covariates appeared to be
 301 limited. Thus, dose adjustment according to TP levels or age is not necessary.
 302 Nevertheless, the current work has identified and quantified sources of
 303 inter-individual variability in pyrotinib response, which has laid the groundwork for
 304 further PK studies as well as precision dosing strategies.

305 Consistent with previous popPK analysis on other TKIs, the minor effect of age
 306 on the effect of pyrotinib was also shown in afatinib, erlotinib, and sunitinib, and all
 307 studies have concluded that no dose adjustment was necessary due to the low clinical
 308 relevance^{13, 14, 15}. As pyrotinib is highly lipophilic ($\log P = 4.475$)^{15, 16}, the influence
 309 of age on pyrotinib distribution volume revealed in this study could be explained by
 310 age-related increase of fat and changes in adipose tissue.

311 The influence of TP level on Vd/F can be explained by the affinity of pyrotinib to
 312 human plasma protein. The TP represents the total amount of albumin and globulin,
 313 both of which are vital physiological components. According to previous findings, the

314 α , β -unsaturated amide structure of pyrotinib molecule is highly affinitive to proteins,
 315 and able to covalently bind to human plasma protein ^{1,8}. Thus, 86.9–99.7% of
 316 pyrotinib was bound to plasma proteins following oral administration ². As a result,
 317 patients with higher protein levels would experience higher pyrotinib plasma
 318 concentration. Most patients included in our analysis had normal TP levels; therefore,
 319 whether patients with extremely low TP levels, such as those under poor nutrition
 320 status, need dosage adjustment should be further studied with a larger patient
 321 population.

322 Our study found that concomitant use of montmorillonite powder can decrease
 323 the bioavailability of pyrotinib by 50.3%, whereas occurrence of diarrhea failed to be
 324 included as a significant covariate affecting the pyrotinib response. Montmorillonite
 325 powder is an adsorbent commonly prescribed for diarrhea treatment ¹⁸. Due to its
 326 unique structure as an aluminosilicate, montmorillonite can strongly adsorb to toxins,
 327 and protect the mucosal barrier, by binding mucous glycoproteins and preventing
 328 toxin absorption ¹⁹. Therefore, it is believed that concomitant use of an adsorbent
 329 could reduce the bioavailability of pyrotinib through adsorption or decreasing its
 330 systemic absorption ²⁰.

331 Considering the possibility that the occurrence of diarrhea could also impede
 332 drug absorption in the GI tract ²¹, confounding bias cannot be excluded due to the
 333 following limitations: First, the impact of non-adsorbent antidiarrheals was not
 334 investigated due to data unavailability. Second, occurrence of diarrhea was included
 335 in the analysis as a dichotomous rather than polytomous covariate due to data

characteristics. Thus, the impact of diarrhea severity was not investigated. However, patients with higher severity of diarrhea have often been treated with montmorillonite powder. In addition, as shown in Table 1, more than 50% of patients who experienced diarrhea were treated with montmorillonite powder. Therefore, the current finding needs to be further supported by studies using a larger sample size.

No significant PK drug-drug interaction was observed between capecitabine and pyrotinib in our analysis. Capecitabine is a weak inhibitor of CYP2C9²². Pyrotinib is a major substrate of CYP3A4 (>75%) and minor substrate of CYP3A5¹. The combination of pyrotinib and capecitabine has been approved as treatment for HER2-positive advanced breast cancer. Our study suggests that combining these drugs does not compromise the PK of either drug.

Several limitations in our study should be addressed. First, the study included only Chinese female patients with breast cancer. While pyrotinib use is expanding to other solid tumors characterized by HER2 overexpression, whether the conclusions presented here could be generalized to patients of another cancer type, or populations of different races or sexes, remains to be further investigated. Second, as the dose-response of pyrotinib has not been well-established, the applicability of the current PK model for optimizing clinical dosing strategies is limited.

5. Conclusion

In this study, a popPK model of pyrotinib for patients with advanced or metastatic breast cancer was developed for the first time. The concomitant use of

357 montmorillonite powder for diarrhea treatment was shown to decrease the
 358 bioavailability of pyrotinib by 50.3%. Furthermore, no PK interaction was shown
 359 between pyrotinib and capecitabine. While pyrotinib distribution volume can be
 360 significantly affected by patient age and TP levels, the magnitude of the impact was
 361 limited, thus no dosage adjustments were recommended.

362 **Acknowledgements**

363 We thank Dr. Guang-li Ma, Dr. Yu-ya Wang, and Miss Mei-xia Chen from Jiangsu
364 Hengrui Medicine Co. Ltd for critical reviewing of the work. We also thank Editage
365 (www.editage.cn) for English language editing.

366 **CRediT author statement**

367 **Hai-ni Wen:** Methodology, Validation, Visualization, Writing – Original Draft,
368 Writing - Review & Editing. **Yi-xi Liu:** Methodology, Software, Formal analysis,
369 Writing -Original Draft, Writing - Review & Editing. **Da Xu:** Data Curation, Writing
370 - Review & Editing. **Kai-jing Zhao:** Data Curation, Writing - Review & Editing.
371 **Zheng Jiao:** Conceptualization, Methodology, Supervision, Writing - Original Draft,
372 Writing -Review & Editing.

373 **Conflicts of interest**

374 This study was funded by Jiangsu Hengrui Medicine Co. Ltd. Da Xu, Kai-jing Zhao
375 are employees of Jiangsu Hengrui Medicine Co. Ltd.

376 **Reference**

- 377 1. Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: A novel
378 irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety
379 profiles for the treatment of breast cancer. *Eur J Pharm Sci.* 2017;110:51-61.
380 doi:10.1016/j.ejps.2017.01.021
- 381 2. Blair HA. Pyrotinib: First Global Approval. *Drugs.* 2018;78(16):1751-1755.
382 doi:10.1007/s40265-018-0997-0
- 383 3. Zhou C, Li X, Wang Q, et al. Pyrotinib in *HER2* -Mutant Advanced Lung
384 Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter,
385 Open-Label, Single-Arm, Phase II Study. *J Clin Oncol.* July
386 2020;JCO.20.00297. doi:10.1200/JCO.20.00297
- 387 4. Gao Z, Song C, Li G, et al. Pyrotinib treatment on HER2-positive gastric
388 cancer cells promotes the released exosomes to enhance endothelial cell
389 progression, which can be counteracted by apatinib. *Onco Targets Ther.*
390 2019;12:2777-2787. doi:10.2147/OTT.S194768
- 391 5. Ma F, Ouyang Q, Li W, et al. Pyrotinib or Lapatinib Combined With
392 Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes,
393 Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. *J Clin*
394 *Oncol.* 2019;37(29):2610-2619. doi:10.1200/JCO.19.00108
- 395 6. Li Q, Guan X, Chen S, et al. Safety, efficacy, and biomarker analysis of
396 pyrotinib in combination with capecitabine in HER2-positive metastatic breast

397 cancer patients: A phase I clinical trial. *Clin Cancer Res.*
398 2019;25(17):5212-5220. doi:10.1158/1078-0432.CCR-18-4173

399 7. Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a
400 novel irreversible Pan-ERBB receptor tyrosine kinase inhibitor, in patients with
401 human epidermal growth factor receptor 2-positive metastatic breast cancer. *J*
402 *Clin Oncol.* 2017;35(27):3105-3112. doi:10.1200/JCO.2016.69.6179

403 8. Meng J, Liu X yun, Ma S, et al. Metabolism and disposition of pyrotinib in
404 healthy male volunteers: covalent binding with human plasma protein. *Acta*
405 *Pharmacol Sin.* 2019;40(7):980-988. doi:10.1038/s41401-018-0176-6

406 9. Yunting Zhua, Liang Lia, Ge Zhang, Hong Wan, Changyong Yang, Xingxing
407 Diao, Xiaoyan Chen, Lianshan Zhang DZ. Metabolic characterization of
408 pyrotinib in humans by ultra-performance liquid chromatography/quadrupole
409 time-of-flight mass spectrometry. *J Chromatogr B.* 2016;1033-1034:117-127.
410 doi:10.1016/J.JCHROMB.2016.08.009

411 10. Malik AY, Foster C. The revised Declaration of Helsinki: cosmetic or real
412 change? *J R Soc Med.* 2016;109(5):184-189. doi:10.1177/0141076816643332

413 11. Donohue MC, Overholser R, Xu R, Vaida F. Conditional Akaike information
414 under generalized linear and proportional hazards mixed models. *Biometrika.*
415 2011;98(3):685-700. doi:10.1093/biomet/asr023

416 12. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected
417 visual predictive checks for diagnosing nonlinear mixed-effects models. *AAPS*
418 *J.* 2011;13(2):143-151. doi:10.1208/s12248-011-9255-z

- 419 13. Nakao, K., Kobuchi, S., Marutani, S. et al. Population pharmacokinetics of
420 afatinib and exposure-safety relationships in Japanese patients with EGFR
421 mutation-positive non-small cell lung cancer. *Sci Rep* 9, 18202 (2019).
422 <https://doi.org/10.1038/s41598-019-54804-9>
- 423 14. Thomas F, Rochaix P, White-Koning M, et al. Population pharmacokinetics of
424 erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and
425 neck squamous cell carcinoma. *Eur J Cancer*. 2009;45(13):2316-2323.
426 doi:10.1016/j.ejca.2009.05.007
- 427 15. Hopkins, AM, Menz, BD, Wiese, MD, et al. Nuances to precision dosing
428 strategies of targeted cancer medicines. *Pharmacol Res Perspect*. 2020;
429 8:e00625. <https://doi.org/10.1002/prp2.625>
- 430 16. Gérard S, Bréchemier D, Lefort A, et al. Body composition and anti-neoplastic
431 treatment in adult and older subjects - A systematic review. *J Nutr Health*
432 *Aging*. 2016;20(8):878-888. doi:10.1007/s12603-015-0653-2
- 433 17. Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung
434 cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase
435 inhibitor pyrotinib. *Ann Oncol*. 2019;30(3):447-455.
436 doi:<https://doi.org/10.1093/annonc/mdy542>
- 437 18. Gao X, Miao R, Tao Y, Chen X, Wan C, Jia R. Effect of Montmorillonite
438 powder on intestinal mucosal barrier in children with abdominal
439 Henoch-Schonlein purpura: A randomized controlled study. *Medicine*
440 *(Baltimore)*. 2018;97(39):e12577. doi:10.1097/MD.00000000000012577

- 441 19. Pérez-Gaxiola G, Cuello-García CA, Florez ID, Pérez-Pico VM. Smectite for
442 acute infectious diarrhoea in children. *Cochrane Database Syst Rev*.
443 2018;4(4):CD011526. doi:10.1002/14651858.CD011526.pub2
- 444 20. Magnoli AP, Alonso VA, Cavaglieri LR, Dalcero AM, Chiacchiera SM. Effect
445 of monogastric and ruminant gastrointestinal conditions on in vitro aflatoxin
446 B1 adsorption ability by a montmorillonite. *Food Addit Contam Part A Chem*
447 *Anal Control Expo Risk Assess*. 2013;30(4):743-749. doi:10.1080/19440049.
448 2013.784398
- 449 21. Effinger A, O'Driscoll CM, McAllister M, Fotaki N. Impact of gastrointestinal
450 disease states on oral drug absorption - implications for formulation design - a
451 PEARRL review. *J Pharm Pharmacol*. 2019;71(4):674-698. doi:10.1111/
452 jphp.12928
- 453 22. Gunes A, Coskun U, Boruban C, et al. Inhibitory Effect of 5-Fluorouracil on
454 Cytochrome P450 2C9 Activity in Cancer Patients. *Basic Clin Pharmacol*
455 *Toxicol*. 2006;98(2):197-200. doi:10.1111/j.1742-7843.2006.pto_304.x

456 Tables

457 **Table 1. Study designs and pharmacokinetic sampling strategies for the investigated**
458 **population**

Study	BLTN-Ib (NCT01937689)	BLTN-Ic (NCT02361112)
Study design/objective(s)	Phase I, single arm, open label, dose-escalation study of pyrotinib monotherapy	Phase I, single arm, open label, dose-escalation study of pyrotinib in combination with capecitabine
Study population and age range	Chinese female patients with HER2 positive advanced breast cancer, 18 to 70 years old	Chinese female patients with HER2 positive metastatic breast cancer, 18 to 70 years old
No. of patients enrolled / patients enrolled in the analysis/ PK data points	36/36/882	29/23/554
Dosing Regimen	80mg-QD (3)	160mg-QD (3) plus capecitabine
(No. of patients)	160mg-QD (8)	240mg-QD (3) plus capecitabine
	240mg-QD (8)	320mg-QD (11) plus capecitabine
	320mg-QD (9)	400mg-QD (11) plus capecitabine
	400mg-QD (8)	
Sampling time frame	28 days (first cycle)	14 days (first cycle)
Time points of PK sampling	Day 1: pre-dose, 1, 2, 3, 4, 5, 6, 8, 12, 24h after dose; Day 28: pre-dose, 1, 2, 3, 4, 5, 6, 8, 12, 24h after dose.	Day 1: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24h after dose; Day 14: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24h after dose;

459 Note: In BLTN-Ic study, capecitabine was dosed by 1,000 mg/m² twice daily. PK, pharmacokinetics;
460 QD, once daily.

461

Table 2. Baseline demographics and disease characteristics of included patients.

Characteristics	Total Population	BLTN-Ib	BLTN-Ic
No. of patients	59 (100%)	36 (61.0%)	23 (39.0%)
Female	59 (100%)	36 (100%)	23 (100%)
No. of observations	1152 (100%)	670 (58.16%)	482 (41.84%)
Age (years)	47 (24-66)	46 (29-66)	47 (24-59)
Total Body Weight (kg)	62.7±8.36	63.0±8.97	62.4±7.43
	61 (48-85)	61 (48-85)	60.5 (49.5-77)
Body mass index (kg/m ²)	24.3±3.32	24.6±3.62	23.9±2.82
	24.0 (18.3-36.8)	24.1 (18.3-36.8)	23.0 (19.1-29.6)
Aspartate aminotransferase (U/L)	28.4±19.3	26.5±14.2	31.0±24.5
	21 (9-118)	22 (11-83)	21 (9-118)
Alanine aminotransferase (U/L)	23.2±19.7	21.7±15.1	25.3±24.6
	18 (4-128)	18 (5-105)	18 (4-128)
Total bilirubin (U/L)	9.11±3.82	8.22±3.00	10.4±4.44
	8.2 (3.7-23.3)	7.80 (3.00-18.5)	9.5 (3.7-23.3)
Albumin (g/L)	44.6±3.42	44.2±3.45	45.2±3.29
	44.6 (30.5-52.9)	44.4 (30.5-51.2)	45.9 (36.2-52.9)
Globulin (g/L)	28.5±4.41	29.5±4.10	27.1±4.47
	28.3 (17.8-40.4)	29.3 (22.5-38.4)	26.4 (17.8-40.4)
Total protein (g/L)	73.1±4.67	73.7±4.61	72.3±4.65
	72.8 (60.7-84.5)	73.0 (66.5-84.5)	72.04 (60.7-83.5)
Serum creatinine (μmol/L)	61.4±11.3	61.1±12.2	61.8±9.89
	61.0 (36.0-86.0)	36.0 (36.0-84.0)	62.0 (43.0-84.0)
Estimated glomerular filtration rate (mL/min)	105±29.7	106±30.4	105±28.7
	99.7 (44.4-190)	99.1 (44.4-187)	99.7 (61.4-190)
Diarrhea	115/1152 (9.98%)	36/670 (5.37%)	79/482 (16.3%)
Concomitant medication			
Montmorillonite powder	68/1152 (5.90%)	0/670 (0%)	68/482 (14.11%)
Capecitabine	482/1152 (41.84%)	0/670 (0%)	482/482 (100%)

Note: Estimated glomerular filtration rate (eGFR) was calculated with CKD-EPI formula for female and non-black as follows: $eGFR \text{ (mL/min)} = 141 \times \min(\text{Scr} / 0.7, 1)^{-0.329} \times \max(\text{Scr} / 0.7, 1)^{-1.209} \times 0.993^{\text{Age}} \times 1.018$, unit of Scr as mg/dL. The body mass index values were provided by the original dataset rather than calculated from height and weight.

Data were expressed as mean ± standard deviation with median (range) for continuous variable, and number (percentage) for categorical variable.

Table 3. Population pharmacokinetic parameter estimates of final model and bootstrap evaluation.

Parameter	Final model		Bootstrap		Relative
	Estimates	RSE%	Median	2.5th-97.5th percentile	Bias (%)
Structural model parameter					
CL	147	6.40	147	129–167	-0.08%
V	2270	7.00	2276	1972–2593	0.28
k_a	0.357	11.10	0.358	0.291–0.443	0.28
MP on F	0.497	14.50	0.497	0.338–0.619	-0.03
AGE on V	0.654	21.10	0.652	0.342–0.917	-0.28
TP on V	-1.94	32.90	1.89	0.698–3.34	-2.78
Between-subject variability					
ω_{CL} (%CV)	50.20	25.10	48.92	37.5–62.3	-2.55
ω_V (%CV)	40.12	23.30	39.08	29.4–48.8	-2.59
ω_{ka} (%CV)	59.41	26.10	58.28	42.0–74.7	-1.91
ω_{CL-V} (%CV)	82.90	25.60	82.50	81.1–84.9	-0.48
Residual unexplained variability					
Proportional1 (%CV)	25.30	17.00	24.87	19.4–29.6	-1.68
Additive 1 (SD)	0.0071	55.20	0.0073	0.00326–0.0127	2.54
Proportional2 (%CV)	18.60	27.20	18.40	13.2–23.5	-1.08
Additive 2 (SD)	0.0150	27.20	0.0150	13.2–23.5	-0.14

AIC, Akaike information criterion; CL, clearance (L/h); k_a , absorption rate constant; V, volume (L); MP on F, influence of co-administration of montmorillonite powder for absolute bioavailability; AGE on V, influence of age for volume; TP on V, influence of total protein for volume; ω_{CL} , between-subject variability of clearance; ω_V , between-subject variability of volume; ω_{ka} , between-subject variability of absorption rate constant; ω_{CL-V} , covariance of clearance and volume; Proportional1, proportional error of Ib study; Additive1, additive error of Ib study; Proportional2, proportional error of Ic study; Additive2, additive error of Ic study.

481 **Figure legends:**

482 **Figure 1. Goodness-of-fit plots of the final population-pharmacokinetic model.**

483 The red line represents the locally weighted scatterplot smoothing line.

484

485 **Figure 2. Prediction-corrected visual predictive check of the final model.**

486 Dots represent the observed data. Solid lines represent the 5th (blue), 50th (red bold),
487 and 95th (blue) percentiles of the observed data. Shaded areas represent
488 nonparametric 95% confidence intervals for the 5th (light blue), 50th (light red), and
489 95th (light blue) percentiles of the corresponding model-predicted percentiles.

490

491 **Figure 3. Simulated median pyrotinib plasma concentration-time curves**
492 **following oral administration of 400 mg once daily.**

493 The typical reference patient was 47 years old and had total protein levels of 72.8 g/L.

494 The solid lines represent the median values of 1000 simulations, and the shaded area
495 is the 95% prediction interval.